Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Case report of neuroleptic malignant syndrome with prolonged mental changes and severe dyskinesia

Case report of neuroleptic malignant syndrome with prolonged mental changes and severe dyskinesia INTRODUCTIONNeuroleptic malignant syndrome (NMS) is a rare but lethal adverse response to antipsychotic drugs that is characterized by hyperthermia, muscular rigidity, altered consciousness, and autonomic instability. Due to an increased awareness of this drug‐induced reaction, as well as earlier diagnosis, and a shift towards the use of atypical antipsychotics, the incidence of NMS has declined from 3% to 0.01%‐0.02% (Stübner et al., ). Nonetheless, NMS remains a significant source of morbidity and mortality among patients receiving antipsychotics, with a mortality rate of 5.6% (Pileggi & Cook, ). Moreover, NMS often requires a stay in an intensive care unit, which could potentially interrupt psychiatric care (Strawn, Keck, & Caroff, ). Here, a case of NMS induced by quetiapine and haloperidol is presented. In addition to the classic features of NMS, the patient showed prolonged mental changes and prominent dystonia and oral dyskinesia that lasted for 26 days.CASE PRESENTATIONA 42‐year‐old woman presented at hospital with recently developed psychotic symptoms that included persecutory delusions, disorganized behavior, and speech. She had never experienced psychotic symptoms before; this was her first visit to the hospital, and her psychotic symptoms gradually increased during the first month after her initial visit.Upon admission, the patient's dose of quetiapine http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asia-Pacific Psychiatry Wiley

Case report of neuroleptic malignant syndrome with prolonged mental changes and severe dyskinesia

Chung, Youn Jae; Lee, Seung Jae
Asia-Pacific Psychiatry , Volume 10 (1) – Jan 1, 2018
Download PDF
3 pages

Loading next page...
 
/lp/wiley/case-report-of-neuroleptic-malignant-syndrome-with-prolonged-mental-0hVfkzOW0B

References (20)

Publisher
Wiley
Copyright
© 2018 John Wiley & Sons Australia, Ltd
ISSN
1758-5864
eISSN
1758-5872
DOI
10.1111/appy.12303
pmid
29464897
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONNeuroleptic malignant syndrome (NMS) is a rare but lethal adverse response to antipsychotic drugs that is characterized by hyperthermia, muscular rigidity, altered consciousness, and autonomic instability. Due to an increased awareness of this drug‐induced reaction, as well as earlier diagnosis, and a shift towards the use of atypical antipsychotics, the incidence of NMS has declined from 3% to 0.01%‐0.02% (Stübner et al., ). Nonetheless, NMS remains a significant source of morbidity and mortality among patients receiving antipsychotics, with a mortality rate of 5.6% (Pileggi & Cook, ). Moreover, NMS often requires a stay in an intensive care unit, which could potentially interrupt psychiatric care (Strawn, Keck, & Caroff, ). Here, a case of NMS induced by quetiapine and haloperidol is presented. In addition to the classic features of NMS, the patient showed prolonged mental changes and prominent dystonia and oral dyskinesia that lasted for 26 days.CASE PRESENTATIONA 42‐year‐old woman presented at hospital with recently developed psychotic symptoms that included persecutory delusions, disorganized behavior, and speech. She had never experienced psychotic symptoms before; this was her first visit to the hospital, and her psychotic symptoms gradually increased during the first month after her initial visit.Upon admission, the patient's dose of quetiapine

Journal

Asia-Pacific Psychiatry – Wiley

Published: Jan 1, 2018

There are no references for this article.